AKT1 and prostate cancer: Dose-dependent responses in PTEN-null and PTEN-low prostate cancer lines have also been observed following ipatasertib treatment, further supporting the finding that AKT inhibition can inhibit PTEN-deficient prostate cancer growth [210].